Pinealon (EDR): Evidence, Mechanism, Dosing & Legal Status

Pinealon is a synthetic ultrashort tripeptide — glutamic acid, aspartic acid, arginine (Glu-Asp-Arg; one-letter EDR) — from Vladimir Khavinson's St. Petersburg short-peptide or "bioregulator/cytogen" program, marketed for neuroprotection, cognition and longevity.1 Its popularity in nootropic circles is real; its proof in humans is not. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Pinealon is not an FDA-approved drug; it is sold as a "research chemical not for human use" and falls under WADA's non-approved-substance class. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Pinealon and how does it work?

Pinealon is a synthetic linear tripeptide, H-Glu-Asp-Arg-OH, CAS 175175-23-2, molecular formula C₁₅H₂₆N₆O₈, molecular weight about 418.4 g/mol.5 It belongs to Khavinson's cytogen short-peptide family — ultrashort two-to-four amino acid peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology and proposed to act as tissue-specific gene regulators.4 The "pinealon" name reflects a proposed neuroendocrine target, not its source; the EDR motif is described as derived from the cortical polypeptide preparation Cortexin.1

The distinguishing — and least-verified — claim is the mechanism. Unlike receptor-ligand peptides, EDR is proposed to enter cells, reach the nucleus and bind DNA at specific short sequences, thereby modulating transcription of neuroprotective genes. Molecular-modeling work reports EDR docking to hexanucleotide sites such as d(CCTGCC) and d(CCAGC) in the promoter regions of genes including SOD2, GPX1, PPARA, PPARG, CASP3, NES, GAP43 and APOE.1 This DNA-binding, gene-targeting model is largely in silico plus single-group experimental support and has not been independently confirmed; the published reviews on PubMed Central frame it as a hypothesis rather than established pharmacology, and it should be read that way (see the open-access review at PMC7795577).1 Downstream, in rat cerebellar granule cells EDR delayed homocysteine-induced ERK1/2 activation and showed an inhibitory effect on the MAPK/ERK pathway alongside ROS suppression.2 No formal human pharmacokinetic data — Cmax, half-life, bioavailability — have been published; treat all PK statements as unverified.1

What is the evidence by indication?

The reproducible signal is in vitro and in rodents; there is no human efficacy trial for any indication. Every row below is therefore best understood as preclinical evidence, graded C — except the human cognition observation, which grades D.

The antioxidant-neuroprotection evidence is the strongest. In the foundational study, Pinealon dose-dependently restricted ROS accumulation in rat cerebellar granule cells, peripheral-blood neutrophils and PC12 cells under oxidative stress from receptor-dependent agents (ouabain, homocysteine) and non-receptor agents (hydrogen peroxide), and reduced necrotic cell death.2 In rodent hypoxia models, EDR restored brain SOD2 and GPX1 activity toward hypoxia-resistant levels, reduced hydroperoxides and prevented caspase-3 activation in neurons.1 In a methionine-loading rat model of prenatal hyperhomocysteinemia, maternal Pinealon improved offspring spatial learning and reduced ROS and necrotic cell counts — notably without lowering offspring homocysteine, implying a downstream protective rather than metabolic effect.3

The human evidence is weak. The most-cited datapoint is an uncontrolled clinical observation in patients with traumatic-brain-injury sequelae and cerebrasthenia, in which oral Pinealon added to standard therapy was reported to improve memory and emotional balance, reduce headache burden and lower error rates.1 This is not a randomized controlled trial: it is small, open, single-group and reported chiefly through review channels — so human cognitive benefit is unproven, Grade D. Broad longevity claims rest on the wider Khavinson program (animal lifespan plus non-blinded Russian clinical data), not on Pinealon human trials.4

What doses appear in the literature?

Reported strictly as information, not a protocol. No validated human dose, frequency, route or safe upper limit has been established.1 In cell culture, effects appear at nanomolar concentrations — roughly 1 to 100 nanomolar — with dendritic-spine rescue reported around 200 nanograms per milliliter.2 Rodent studies use low microgram-per-kilogram parenteral or oral dosing across short courses, with specifics varying by model.3 The single uncontrolled human observation in TBI cerebrasthenia cited oral Pinealon at about 0.2 milligrams twice daily for 20 to 30 days alongside standard therapy; the Khavinson class is typically used as short 10-to-30-day courses.1 Pinealon is sold as a lyophilized research-use-only powder, and vendor reconstitution protocols are not derived from controlled human trials — they are excluded here as non-evidentiary.4

How safe is Pinealon?

There is no formal human safety dataset of any quality: no published adverse-event profile, no toxicology dossier in the FDA or EMA sense, and no long-term human data for Pinealon specifically.4 The broader Khavinson short-peptide class is described anecdotally and in program reports as well tolerated in short courses with no serious adverse events flagged, but this comes from the originating group and non-blinded Russian clinical use — low-quality evidence for safety.4 Because the proposed mechanism is gene-expression modulation and stimulation of cell proliferation, an unquantified theoretical concern is proliferative or oncologic signaling — though the class is conversely reported to suppress tumorigenesis in rodents; both directions are preclinical and unsettled.1 No human drug interactions are characterized. Precautionary contraindications include pregnancy and lactation, children and people with active malignancy. The largest practical hazard is product quality: research-use-only powders are unregulated for human use, with no guaranteed identity, purity, sterility or endotoxin content.4

What is the FDA and WADA status in 2026?

Pinealon is not FDA-approved for any indication and has no recognized off-label use, since off-label status applies only to approved drugs. It is not a permitted compounding bulk substance — it is treated as effectively Category 2 and is not on the 503A interim list, so it cannot be lawfully compounded by 503A pharmacies or 503B outsourcing facilities for clinical use.7 It is sold for research use only and not for human consumption, and marketing it with therapeutic claims (cognition, anti-aging, neuroplasticity) renders it an unapproved new drug; FDA enforcement attention to this class has been reported through 2025 into 2026.8 It is not a DEA-controlled substance. Registered Khavinson pharmaceuticals such as Cortexin and Thymalin exist in Russia, but Pinealon itself is not an approved medicine in the US or EU.4

For athletes the picture is one of regulatory exclusion. Pinealon is not listed by name on the WADA Prohibited List, but as a substance not approved for human therapeutic use by any government regulator, it falls under WADA class S0 (non-approved substances), which captures research-only and unapproved peptides — meaning it should be treated as prohibited in sport at all times.6 Any WADA-tested athlete should treat it as banned and check the current annual Prohibited List directly.6

Bottom line. Pinealon (EDR / Glu-Asp-Arg) is a genuinely interesting ultrashort peptide with a coherent preclinical antioxidant-neuroprotection story — dose-dependent ROS suppression, anti-apoptotic effects, SOD2/GPX1 upregulation, dendritic-spine preservation and improved maze learning in rodents — plus a provocative but largely unverified "binds DNA to regulate genes" mechanism. What is proven is cell and rodent neuroprotection (Grade C); what is hyped is human cognition, anti-aging and Alzheimer's benefit (Grade D). Nearly all data come from a single research group, the DNA-binding mechanism is unconfirmed, and there is no human PK or formal safety dataset. For an athlete it is effectively prohibited under S0; for everyone else it remains an experimental compound that is not legally a medicine in the US or EU as of 2026. Regulatory facts here should be re-verified against primary FDA and WADA sources before relying on them.